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Abstract Chronic total coronary occlusions (CTO) are docu-
mented in approximately one fifth of diagnostic invasive coro-
nary angiographies (ICA). Percutaneous coronary interventions
(PCI) of CTO are challenging and are accompanied by higher
complication and lower success rates in comparison with non-
CTO PCI. Scrutinous evaluation of ischemia and viability to
justify percutaneous revascularization is therefore of impor-
tance to select eligible patients for such a procedure.
Furthermore, knowledge of the anatomical features of the oc-
clusion may predict the chances of success of PCI CTO and
could even guide the procedural strategy to augment the likeli-
hood of recanalization. Positron emission tomography (PET) is
unequivocally accepted as the reference standard for ischemia
and viability testing, whereas coronary computed tomography
angiography (CCTA) currently allows for non-invasive detailed
three-dimensional imaging of the coronary anatomy that adds
morphological information over two-dimensional ICA. Hybrid
PET/CT could therefore be useful for optimal patient selection
as well as procedural planning. This review discusses the po-
tential value of PET/CT to guide PCI in CTOs.
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Abbreviations
CAD Coronary artery disease
CTO Chronic total coronary occlusion
CABG Coronary artery bypass grafting surgery
OMT Optimal medical treatment
PCI Percutaneous coronary intervention
LV Left ventricular
PET Positron emission tomography
CCTA Coronary computed tomography angiography
ICA Invasive coronary angiography
MPI Myocardial perfusion imaging
SPECT Single photon emission computed tomography
CMR Magnetic resonance imaging
MPR Multiplanar reconstructions
MIP Maximum intensity projections
18F-FDG 18F-deoxyglucose
Introduction
Coronary artery disease (CAD) is the leading cause of death in
the Western world. In 18–35 % of patients with known or
suspected CAD, a chronic total coronary occlusion (CTO) is
involved [1–4]. A CTO is defined as native coronary artery
with absent or minimal antegrade blood flow for >12-week
duration [5, 6]. Patients with CTOs are treated differently from
non-occlusive CAD and are less likely to undergo revasculari-
zation, either percutaneously or surgically. For CTO patients
who are offered revascularization, coronary artery bypass
grafting surgery (CABG) is the mainstay with a 3:1 ratio [1].
The reluctance of physicians to refer patients for
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revascularization is based on the false assumption that symp-
toms are easily controlled by optimal medical therapy (OMT)
and that the myocardium subtended by the CTO artery is often
non-viable and/or non-ischemic that would not benefit from
revascularization. Owing to the traditionally low success rate
of about 50–70 % and relatively high complication rate, percu-
taneous coronary intervention (PCI) of CTO is empirically
attempted in less than 15 % of eligible patients [1, 7–12].
However, successful recanalization of a CTO is accompanied
by symptom relief, recovery of left ventricular (LV) function,
and improved survival as opposed to patients in whom the
procedure was unsuccessful [3, 7, 13–21].
In recent years, advances in guide wire technology and im-
plementation of dissection and re-entry techniques have
resulted in augmented success rates exceeding 90 % in the
hands of experienced CTO centers [22–24]. Nonetheless, these
procedures are still accompanied by slightly higher complica-
tion rates, contrast and radiation burden, and costs in compari-
son with non-CTO PCI [5, 25–27]. Scrutinous evaluation of
ischemia and viability to justify percutaneous revascularization
is therefore of importance to select eligible patients for such a
procedure. Furthermore, knowledge of the anatomical features
of the occlusion may predict the chances of success and could
even guide the procedural strategy to augment the likelihood of
recanalization in an efficient manner [28•, 29••].
The combination of hybrid positron emission tomography
(PET) and coronary computed tomography angiography
(CCTA) nowadays allows for the accurate detection and
Fig. 1 Proposed diagnostic and
treatment algorithm in patients
with a documented chronic total
coronary occlusion (CTO). LV left
ventricular, OMT optimal medical
therapy




Half-life 123 s 9.97 min 76 s 110 min









Mean positron range in tissue 1.1 mm 0.4 mm 2.8 mm 0.2 mm
Scan duration 6 min 20 min 6 min 20 min
Gating/LV function − + + +
Radiation dose (3D) according
to protocol in references
∼0.4 mSv/370 MBq ∼1 mSv/550 MBq ∼0.7 mSv/555 MBq
(2D: ∼2.3 mSv/1850 MBq)
∼2.1 mSv/111 MBq (rest)
∼4.6 mSv/244 MBq (stress)
Exercise protocol compatible − − − +
Quantification Excellent Good Moderate Very good
Image quality Good (parametric images) Very good Good Excellent
PET positron emission tomography,H2
15O oxygen-15-labeled water, 13NH3 13N-labeled ammonia,
82 Rb 82 rubidium,mSvmillisievert,MBqmegabecquerel
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quantification of myocardial ischemia and viability in con-
junction with coronary anatomy and morphology near simul-
taneously. As such, hybrid PET/CT could prove useful in the
clinical work-up of CTO patients to determine eligibility and
plan procedural strategy. This review discusses the potential
value of PET/CT to guide PCI CTO.
Selection of Eligible Patients for Revascularization
of CTO
The decision scheme on the diagnostic work-up for CTO pa-
tients to evaluate eligibility for revascularization is depicted in
Fig. 1. Please note that this algorithm is based on current
international guidelines and is not specifically targeted to
CTO patients but to obstructive CAD in general. Once the
diagnosis of a CTO has been established, usually through a
diagnostic invasive coronary angiogram (ICA), information
pertaining LV function is mandatory. Normal regional LV
function of myocardium subtended by the CTO by definition
excludes non-viability. The decision to proceed to a revascu-
larization procedure is then merely based on the presence and
extent of ischemia. Without documented ischemia, such a
procedure is futile and even hazardous [30] as the patient is
subjected to potential procedural complications without a
clear benefit and OMT suffices. In the majority of cases,
Fig. 2 Extensive myocardial ischemia induced by a CTO LAD. Patient
with a known CTO LAD for over 7 years with NYHA class II was
analyzed with PET to assess the extent of myocardial ischemia before
reconsidering (percutaneous) revascularization. a The proximal total
occlusion of the LAD (white arrow). To appreciate collateralization,
length, and course (white arrow) of the occlusion, a bilateral injection
was performed during a diagnostic invasive coronary angiogram (b). PET
perfusion shows the extensive (c and d) perfusion defect in presence of a
proximal occlusion of the LAD. CTO chronic total occlusion, LAD left
anterior descending artery, NYHA New York Heart Association, PET
positron emission tomography
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however, ischemia is observed. Even the presence of well-
developed collaterals does generally not protect the myocar-
dium against ischemia. An increase in collateral flow reserve
during pharmacological stress has been shown to occur in
only 7 % of patients, while coronary steal can be documented
in a third [31, 32]. When the jeopardized myocardium com-
prises more than 10 % of the LV, revascularization on top of
OMT is considered appropriate irrespective of symptoms [33].
Retrospective analysis of myocardial perfusion studies in
large registries have revealed that such an ischemic burden
holds prognostic relevance and revascularization is associated
with improved outcome [34]. When the extent of ischemia is
less pronounced (i.e., < 10 %), an initial treatment strategy of
OMT is justified and revascularization only contemplated af-
ter inadequate response to medical therapy.
Conversely, when patients exhibit extensive regional wall
motion abnormalities in the affected vascular territory, we
recommend that the diagnostic work-up focus on myocardial
viability rather than ischemia. Without signs of myocardial
viability (i.e., previous (near) transmural myocardial
Fig. 3 Representative cases of a false-negative and false-positive SPECT
result due to limited tracer extraction or attenuation, respectively. False-
negative SPECT result (a) in case of an unmistakable perfusion defect of
the inferior wall on PET (b) of a patient with a chronic total occlusion
(white arrow) of the RCA on ICA (c). False-positive SPECT result (d)
(perfusion defect of the inferior wall) of a patient with normal perfusion
on PET (e) and no obstructive coronary artery disease on ICA (f). SPECT
single photon emission computed tomography,RCA right coronary artery,
ICA invasive coronary angiography; other abbreviations as in Fig. 2
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infarction), similar to lack of ischemia, revascularization is
considered inappropriate as no recovery of function is antici-
pated [35, 36]. Although, it must be noted that revasculariza-
tion of non-viable myocardium might halt the process of pro-
gressive LV remodelling [37]. The presence of substantial
viability warrants revascularization and is accompanied by
recovery of LV function and improved outcome as observed
in both retrospective and prospective studies [35, 38, 39]. The
extent of viability deemed necessary for a clinically relevant
improvement in LV ejection fraction (i.e., >5 percentage
points) is uncertain, but generally ranges from 10 to 25 %
jeopardizedmyocardium [40, 41]. Small quantities of viability
are not associated with recovery of function, but revasculari-
zation could be considered to reduce symptoms not controlled
by medical therapy.
Although the presented literature supports the utilization of
the proposed treatment algorithm, randomized trials on
imaging-guided revascularization are scarce. The PET and
Recovery Following Revascularization (PARR-2) [42] and a
substudy of the Surgical Treatment for Ischemic Heart Failure
Fig. 4 Balanced ischemia on SPECT. Example of a (nearly) normal
SPECT (a) and severely reduced perfusion on positron emission
tomography (PET) (b, c) in case of a significant left main stenosis (white
arrow) and a chronic total occlusion of the RCA (black arrow) on
invasive coronary angiography (d). SPECT is hampered by the relative
nature of the images, whereas quantification with PET allows for
detection of diffusely balanced ischemia. Abbreviations as in Figs. 2
and 3
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(STICH) [43] trial have evaluated the impact of viability as-
sessment on clinical outcomes after CABG and were both
negative. A nuclear substudy of the Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation
(COURAGE) trial suggests that an appreciable reduction of
ischemia is accompanied by a favorable outcome after PCI
[44]. These results were corroborated for CTO patients who
underwent PCI, whereby a baseline ischemic burden >12.5 %
in combination with a reduction >5 % yielded the most favor-
able clinical outcomes [45]. A randomized imaging study on
the merits of ischemia-guided revascularization is, however,
lacking altogether. The ongoing International Study of
Comparative Health Effectiveness with Medical and
Invasive Approaches (ISCHEMIA) trial is attempting to es-
tablish the value of revascularization in patients with a large
ischemic burden in a randomized fashion. More specifically
tailored to PCI-CTO, large observational studies have shown
that a successful percutaneous recanalization results in im-
proved all-cause mortality, lower MACE rates (relative risk:
0.70), and reduced need for CABG as opposed to unsuccess-
ful attempts [13, 18, 19, 46]. Nonetheless, these studies are all
observational in nature and thus prone to confounding.
Currently, the Drug-Eluting Stent Implantation Versus
Optimal Medical Treatment in Patients with Chronic Total
Occlusion (DECISION-CTO) and the Randomized
Mult icentre Tria l to Evaluate the Uti l izat ion of
Revascularization or Optimal Medical Therapy for the
Treatment of Chronic Total Coronary Occlusions (EURO-
CTO) trials are the first studies to more accurately assess the
surplus clinical value of PCI-CTO over OMT alone in a ran-
domized fashion. The results of the aforementioned studies
are eagerly awaited.
Fig. 5 State-of-the-art illustration of fused CCTA and PET of a CTO
RCA. Relative and absolute (normal value >2.3 mL min−1 g−1 [58])
perfusion defect on H2
15O PET perfusion (a, b) fused with CCTA (c)
shows the perfusion defect of the left ventricle in relation to the occluded
segment of the RCA (white arrow). ICA confirmed the precise location of
the coronary occlusion (white arrow) with bilateral contrast injection (d).
CCTA coronary computed tomography angiography; other abbreviations
as in Figs. 2 and 3
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Positron Emission Tomography
Although a large armamentarium of imaging modalities is
available to evaluate myocardial perfusion and viability, PET
is unequivocally accepted as the reference standard for this
task. The following section will place the value of PETwithin
the context of alternative imaging techniques.
Myocardial Perfusion Imaging
Four tracers in particular have been well validated for myo-
cardial perfusion imaging (MPI) with PET [47•]. Of the avail-
able tracers, 82Rb, 13NH3, and H2
15O are the most commonly
used. 18F-flurpiridaz is an emerging perfusion tracer not yet
available for clinical use, but holds great potential and is cur-
rently being tested in phase 3 trials [48–50]. Each of these
tracers possesses unique characteristics with their individual
pros and cons pertaining (costs of) radionuclide production,
physical half-life, image quality, radiation exposure, and com-
patibility with exercise acquisition protocols (Table 1). None
of the perfusion tracers excels on all of these features. Choice
of tracer is therefore multifactorial and frequently depends on
practical and logistical considerations.
Figure 2 shows an example of perfusion PET in a patient
with a CTO of the LAD with collateral filling through a right
ventricular branch. A large perfusion defect can be observed
during hyperemia, whereas resting perfusion is normal. These
images justify an attempt to recanalize the artery for prognos-
tic benefit as already alluded to. In the previous section, diag-
nostic accuracy for MPI with PET to diagnose obstructive
CAD has proven to be excellent. Pooled analysis of diagnostic
studies displays weighted sensitivity, specificity, NPV, and
PPV of 91, 86, 81, and 93 %, respectively [47•]. Moreover,
diagnostic performance of PET is superior to the more com-
monly utilized single photon emission computed tomography
(SPECT) MPI. Increased tracer extraction and higher spatial
resolution of PET allow detection of subtle perfusion defects
that may go undetected with SPECT. In addition, routine at-
tenuation correction of PET significantly reduces false-
positive results that are frequently observed with SPECT
[51]. Figure 3 shows examples of these phenomena. In recent
years, cardiovascular magnetic resonance imaging (CMR) has
emerged as an alternative imaging tool for MPI. CMR has the
advantage of superior spatial resolution, and perfusion can be
visually assessed by first pass imaging of gadolinium-based
contrast agents. Nonetheless, a meta-analysis by Jaarsma et al.
has demonstrated that PET is the imaging modality of choice
to evaluate the functional consequences of CAD with higher
performance over SPECT and CMR [52•]. Another distinct
advantage of PET is the fact that, next to visual assessment
of regional perfusion defects, myocardial blood flow is routine
quantified in absolute terms (i.e., in units of mL min−1 g−1)
and allows to calculate coronary flow reserve (CFR) [53–57].
Quantification of perfusion unmasks conditions of balanced
ischemia whereby visual interpretation of perfusion images
(regardless of the utilized technique like PET, SPECT, or
CMR) can be completely normal and yield false-negative re-
sults in multi-vessel disease. As patients with CTO frequently
exhibit multi-vessel CAD, routine quantification of perfusion
with PETaids in the interpretation of a seemingly normal scan
(Fig. 4). Furthermore, PET/CT allows for near simultaneous
cardiac PET and CCTA to assess perfusion defects in relation
to the coronary anatomy (Fig. 5).
Myocardial Viability Imaging
In approximately half of CTO patients, wall motion abnormal-
ities are observed with electrocardiographic evidence of myo-
cardial infarction in a third of patients [1]. It is of interest to
note that the presence or absence of collaterals does not sig-
nify or excludes viability, respectively [59–61]. In such con-
ditions, viability imaging is advocated. Normal resting perfu-
sion basically indicates intact capillary and sarcolemmal
membranes and is thus confirmatory of viable myocardium.
An irreversible (Bfixed^) perfusion defect, however, does not
mean that the myocardium is not viable as it may represent
either myocardial scarring (non-viable myocardium) or hiber-
nating myocardium, a condition characterized by resting hy-
poperfusion with preserved or even augmented metabolism.
The distinction between these two conditions can be made by
metabolic imaging. The most experience for myocardial sub-
strate metabolism has been obtained with the glucose
Fig. 6 Myocardial viability imaging with PET. Illustration showing a
mismatch of resting MBF and glucose metabolism of the inferolateral
wall indicating viable myocardium (top). A matched resting perfusion
and glucose metabolism defect of the inferior wall, indicating non-
viable myocardium is shown in the bottom image. 82Rb 82rubidium,
18F-FDG 18F-deoxyglucose, SA short axis, HLA horizontal long axis,
VLA vertical long axis; reprint with permission [63]
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analogue 18F-deoxyglucose (18F-FDG) [62]. Figure 6 shows
the imaging patterns of resting MBF and glucose metabolism
in a patient with (mismatch) and without myocardial viability
(match). Although nowadays, there are many alternatives for
myocardial viability testing (e.g., 99mTechnetium SPECT,
low-dose dobutamine echocardiography, and delayed contrast
enhanced CMR), the combination of cardiac perfusion/
metabolism PET is still considered the gold standard with
the highest diagnostic accuracy. PET/CT offers the additional
advantage to fuse the metabolic with the anatomical images to
Fig. 8 Example of precise
occlusion length estimation with
CCTA. Three-dimensional
reconstruction (a), maximum
intensity projections (b), center
line extraction (c), and




and occlusion length in case of a
long LAD occlusion
(white arrows). The occlusion
length (black arrow) was
confirmed with bilateral contrast
injection during ICA (e).
Abbreviations as in Figs. 2, 3,
and 5
Fig. 7 Viability assessment with




perfusion, and metabolism. Due
to fused images, it becomes
possible to precisely distinguish
ischemic viable form non-viable
myocardium. 13NH3 13N-labeled
ammonia, HU Hounsfield units;
other abbreviations as in Fig. 6;
reprint with permission [64]
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more comprehensively evaluate regional viability in relation
to the coronary tree (Fig. 7).
Coronary Computed Tomography Angiography
Over the last decade, CCTA has developed as a valuable non-
invasive alternative for the visualization of coronary anatomy.
Current multislice CT scanners in combination with modern
acquisition protocols enable robust and reproducible assess-
ment of coronary artery morphology with relatively high tem-
poral and spatial resolution accomplished at an acceptable radi-
ation dose [65–68]. CCTA allows to visualize the characteris-
tics of a CTO, which is useful not only for diagnostic purposes
but also for planning a potential interventional strategy. CCTA
even has some advantages over invasive angiography with
three-dimensional reconstructions of the affected segment to
fully appreciate the course and length of the occlusion (Fig. 8).
Definition of CTO on CCTA
A CTO on CCTA is diagnosed if there is complete disconti-
nuity of contrast opacification of the coronary artery lumen in
the cross-sectional views, multiplanar reconstructions (MPR),
and maximum intensity projections (MIP). The time lapse
between the intravenous contrast injection and the contrast
bolus tracking setoff results in less dense and reverse contrast
opacification distal to the occlusion due to collateral flow [69,
70]. Suspicion of a more recent occluded vessel should rise if
there is no distal contrast opacification [71, 72]. Von Erffa
et al. showed that an occlusion length of ≥9 mm on CCTA
predicted a total occlusion on ICAwith 100 % specificity in a
group of 40 consecutive patients with a lesion demonstrating
complete contrast discontinuity on CCTA. Figure 8 shows the
accuracy of occlusion length on CCTA in comparison with
ICA. Nevertheless, differentiation between high-grade steno-
sis and total occlusion remains unreliable due to the relatively
limited spatial resolution of CCTA [73], while the presence of
true lumen antegrade flow is of clinically importance since it
significantly influences the success rate of PCI.
Angiographic Predictors of Success of PCI CTO
Historically, the success rate of PCI CTO ranged between 50
and 70 %, which has resulted in the reluctance to attempt
Table 2 Assessable angiographic features of a CTO
Invasive CCTA
Lesion length ++ +++
Tortuosity ++ +++
Calcification + +++
Proximal cap morphology ++ +
Proximal side branch +++ ++
Bridging collaterals +++ +
True lumen flow ++ +
Vessel course + +++
Landing zone ++ ++
Plaque characteristics + +++
Interventional collaterals ++ +
CTO chronic total occlusion, CCTA coronary computed tomography
angiography
Fig. 9 CCTA coronary course
tracking. ICA of the RCA during
bilateral contrast injection (a) and
corresponding CCTA coronary
course tracking images (b) show
that the course of the occluded
segment is superiorly illustrated
with CCTA in comparison with
ICA. Abbreviations as in Figs. 2,
3, and 5
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percutaneous revascularization [1, 7, 12]. To more adequately
predict the chances of successful antegrade wire crossing
(within 30 min) for appropriate case selection, the Japanese
Multicenter CTO Registry (J-CTO) score was developed
[28•]. The J-CTO score has identified several independent
angiographic predictors of failure being heavy calcification,
bending within the occluded segment, blunt proximal stump,
and occlusion length >20 mm. An additional point in this
scoring system is given for a previous failed attempt. Low J-
CTO scores are thus easily crossed, while high scores are
characterized by high likelihood of failure. One of the issues
in the full assessment of the J-CTO score is the frequent ne-
cessity of simultaneous double arterial injection of the right
and left coronary arteries (see Figs. 2, 7, 8, and 9). These
images are generally not produced during a diagnostic inva-
sive angiogram. These angiographic features, however, can
also be visualized by CCTA and could therefore similarly
aid in the prediction of procedural success (Table 2). Several
Fig. 11 Algorithm for crossing
CTOs. Hybrid approach dictated
by anatomical features of a
chronic total occlusion of a native
coronary artery. LaST limited
antegrade subintimal tracking;
other abbreviations as in Fig. 2;
reprint with permission [29••]
Fig. 10 CTO wire crossing difficulty score appreciated from CCTA and
ICA. The top CCTA (a) and ICA (b) images display a short occlusion
(<20 mm) (white arrow), tapered proximal stump, no calcification, and no
bending of the occluded segment (low CT-RECTOR score). This occlusion
should be approached and probably successfully crossedwith antegrade wire
escalation technique. The bottom CCTA (c) and ICA (d) images clearly
demonstrates a long (>20 mm) (white arrow) calcified occlusion (high CT-
RECTOR score) suggesting that the operator should be able to use dissection
and re-entry techniques before trying to cross this occlusion because anatomy
dictates which approach should be used. Abbreviations as in Figs. 2 and 3
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small-scaled studies have indeed identified very comparable
angiographic CTO characteristics obtained with CCTA that
were associated with PCI CTO failure as those observed in
the J-CTO registry [74–78]. It has even been suggested that
pre-procedural knowledge of the three-dimensional anatomy
of the occlusion may aid in antegrade wire escalation and
crossing of the lesion and thus improve procedural outcome
[79]. Figure 9 illustrates that CCTA can be quite helpful to
appreciate the coronary course of an occluded segment. More
recently, Opolski et al. [80••] reported a CCTA-based scoring
system in 240 CTO patients to predict success of percutaneous
antegrade wire crossing in the Computed Tomography
Registry of Chronic Total Occlusion Revascularization (CT-
RECTOR). Very much like the J-CTO, independent angio-
graphic predictors were occlusion length >20 mm, multiple
occlusions, blunt stump, bending, and severe calcification.
Clinical predictors were previously failed attempt and CTO
duration >12 months or unknown duration. The predictive
value of the CT-RECTOR proved to be superior over the J-
CTO score to predict antegrade wire crossing <30 min (AUC
0.83 vs. 0.71). Figure 10 shows an example of a low and high
CTO difficulty score on CCTA and ICA. These data suggest
that CCTA could be utilized in clinical practice for case selec-
tion and perhaps even for pre-procedural planning to improve
success. There is, however, an important caveat in the inter-
pretation of these data. All of these studies have merely inves-
tigated the likelihood of antegrade wire crossing. Even though
this type of approach is still the mainstay in attempts to per-
cutaneously tackle CTOs, its success rate is low (62 % in the
CT-RECTOR Registry). Dedicated CTO centers that have
adopted the Bhybrid^ approach (i.e., next to antegrade wire
escalation implementing retrograde wire escalation and dis-
section re-entry techniques) nowadays achieve success rates
over 90 % with very acceptable complication rates. This ap-
proach (as depicted in Fig. 11) lets coronary anatomy define
the procedural strategy, but anatomical features and lesion
complexity are not used to select cases [29••]. As such,
CCTA is hardly utilized by hybrid operators. Nonetheless,
pre-procedural CCTA could be useful for antegrade wire op-
erators. Based on non-invasive CT imaging, lesion complexity
and thus chances of success can be accurately assessed and
this information employed to select cases or refer to expert
centers [81].
Conclusions
Percutaneous revascularization of CTOs is less frequently per-
formed as non-occlusive CAD due to technical procedural
challenges, lower likelihood of recanalization, and increased
complication rate. PET/CT allows for non-invasive imaging
of myocardial perfusion and metabolism to objectify the ex-
tent of ischemia and viability. The hybrid images of coronary
anatomy with CT and functional consequences of the CTO
with PET allows for appropriate selection of patients who
are likely to benefit from PCI CTO and facilitate procedural
planning.
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